Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus GG cell extract
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus GG (LGG) cell extract is a postbiotic preparation derived from the standard probiotic strain *Lacticaseibacillus rhamnosus* GG. It is being investigated as a complementary anticancer therapy, particularly for colorectal cancer. Research indicates that the extract, containing bacterial metabolites and cellular components, can selectively induce apoptosis and decrease viability in human colon cancer cell lines (such as HT-29) while providing a cytoprotective effect on normal cells (such as HEK-293) against chemotherapy-induced toxicity. When used in combination with 5-fluorouracil (5-FU), the extract appears to enhance anti-tumor immunity by stimulating the production of Th17-related cytokines, including IL-17A, IFN-γ, and TNF-α.
- Other names
- LGG cell extractLacticaseibacillus rhamnosus GG cell extractLactobacillus rhamnosus GG extract
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-17A (Interleukin-17A)IFNG (Interferon gamma)
Beyond the preview
Go deeper on lactobacillus rhamnosus GG cell extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus GG cell extract.